title: Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.
abstract: OBJECTIVE
  To compare conventional sibling bone marrow transplantation (CBMT), BMT with alternative donor (ABMT), and chemotherapy (CT) for children with acute lymphoblastic leukemia (ALL) and an early first marrow relapse.
  
  
  METHODS
  After informed consent, 214 patients with ALL and early marrow relapse began multiagent induction therapy. One hundred sixty-three patients with fewer than 25% marrow blasts and count recovery at the end of induction (second remission [CR2]) were allocated by donor availability. Fifty patients with sibling donors were allocated to CBMT. Seventy-two patients were randomly allocated between ABMT and CT while 41 patients refused allocation.
  
  
  RESULTS
  Overall, 3-year event free survival from entry is 19% +/- 3%. Thirty-two of 50 CBMT patients (64%) and 19 of 37 ABMT patients (51%) underwent transplantation in CR2 with 3-year disease-free survival of 42% +/- 7% and 29% +/- 7%. The 3-year DFS is 29% +/- 7%, 21% +/- 7%, and 27% +/- 8% for patients allocated to CBMT, ABMT, and CT, respectively. Contrary to protocol, 12 of 35 patients allocated to CT underwent BMT in CR2. Of these, five patients died after BMT and 5 patients relapsed.
  
  
  CONCLUSIONS
  More than one half of patients died, failed reinduction, or relapsed again before 3 months after CR2 (median time to BMT). Intent-to-treat pair-wise comparison of ABMT with CT, CT with CBMT, and CBMT with ABMT yields hazards of 1.2, 1.1, 0.8 with P values of .56, .80, and .36, respectively. Outcomes remain similar and poor for children with ALL and early marrow relapse. BMT is not a complete answer to the challenge of ALL and early marrow relapse.
authors.affiliation: Division of Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, CA, USA. PGaynon@chla.usc.edu
authors.forename: Paul S
authors.initials: PS
authors.lastname: Gaynon
authors.forename: Richard E
authors.initials: RE
authors.lastname: Harris
authors.forename: Arnold J
authors.initials: AJ
authors.lastname: Altman
authors.forename: Bruce C
authors.initials: BC
authors.lastname: Bostrom
authors.forename: John C
authors.initials: JC
authors.lastname: Breneman
authors.forename: Ria
authors.initials: R
authors.lastname: Hawks
authors.forename: David
authors.initials: D
authors.lastname: Steele
authors.forename: Theodore
authors.initials: T
authors.lastname: Zipf
authors.forename: Daniel O
authors.initials: DO
authors.lastname: Stram
authors.forename: Doodjuen
authors.initials: D
authors.lastname: Villaluna
authors.forename: Michael E
authors.initials: ME
authors.lastname: Trigg
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019046:Bone Marrow Neoplasms / Q000601:surgery*; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D035781:Siblings; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome